Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
Takeda buys rights to Ovid’s soticlestat for $856 million
by Megha Satyanarayana
March 5, 2021
| A version of this story appeared in
Volume 99, Issue 8
Takeda Pharmaceutical has agreed to buy Ovid Therapeutics’ developmental seizure treatment, soticlestat, for up to $856 million, including an up-front payment of $196 million. Soticlestat, which inhibits the enzyme cholesterol 24-hydroxylase, reduced seizure frequency in a Phase 2 trial of children with rare neurological diseases. Takeda discovered the drug, then licensed it to Ovid in 2017 for development.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter